EPCO-41. TESSA JOWELL BRAIN MATRIX INTERIM ANALYSIS: FEASIBILITY OF IDENTIFYING THERAPEUTIC TARGETS FOR GLIOMA USING NHS WHOLE GENOME SEQUENCING

Abstract BACKGROUND AND AIMS The Tessa Jowell BRAIN MATRIX (TJBM) is a programme of work aimed at improving the knowledge of and treatment for glioma, comprising a platform study with subsequent clinical trials. A key objective is to evaluate the feasibility of using whole genome sequencing (WGS), provided by the NHS Genomic Medicine Service in England, to identify therapeutic targets and guide precision medicine for glioma patients. METHOD Interim analysis of first 500 patients from 11 centres recruited to the TJBM study (14/Dec/2020-31/Jan/2025) with recruitment ongoing. Data snapshot 30/Apr/2025. Analysis conducted in R version 4.3.1. RESULTS For 500 recruited patients: median age is 57 years (interquartile range 45-66); male gender 62 %, ethnicity self-reported as White (92%), Asian/Asian British (3%), Black/Black British, Caribbean or African (2%), other ethnic group (2%). The integrated histological-molecular diagnosis is adult diffuse glioma (97%) with the majority comprising high grade glioma (80%). Currently, 161 (40%) of the 379 patients registered at English trial centres have a completed WGS report. Median time from sample collection to WGS report is 193 days (interquartile range 98-405). We review the timings through critical steps within the NHS WGS infrastructure and reported variants. CONCLUSION Ethnic inequalities must be better understood and addressed, to ensure equitable representation in genomics and access to precision medicine. Geographical variability and logistical challenges in the NHS WGS pathway hinder timely and uniform access for glioma patients across the UK. Evaluation and accreditation of novel sequencing techniques and diagnostic tools are required to accelerate the identification and delivery of targeted therapies. The TJBM infrastructure provides a trial-competent network to evaluate innovative models of genomic care and implement emerging genomic technologies. Strong collaboration with academic and industry partners will be key to accelerate the translation of scientific advances into clinical trials and deliver tangible benefits for patients.